Australia: Where Value Beats Cost
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is going through globally: the country deals with patent cliffs, companies are…
Address: PO Box 196 Hawthorn Victoria 3122
Tel: (03) 8823 7333
Web: http://www.servier.com.au/home/default.asp
In just over 20 years, turnover has increased from $1 million in 1984 to $107 million for 2009. The number of people employed has risen steadily. The Sales force has grown from 6 representatives in 1984 spread across all Australian regions to in excess of 120 representatives today, but has maintained its reputation throughout this time as being amongst one of the best trained, most professional and most productive in Australia.
Servier’s activities in Australia commenced in 1979 with the launch of the anti-diabetic agent- Diamicron
Pivotal development work for the group’s flagship product Coversyl, which led to more than 30 publications from Australian researchers prior to marketing approval, culminated with the launch of Coversyl 2mg and 4mg in 1992.
In 1999 The International Centre for Therapeutic Research was established in Australia- The first outside of Europe and now has a staff in excess of 30 involved in phase l,ll and lll clinical research.
By January 1999 the company had outgrown it’s head office of 15 years and moved to it’s new purpose built office in Hawthorn, Melbourne, which saw the divisions of Sales/Marketing and Research all housed under the one roof.
Coversyl 8mg was launched in February 2004 and already contributes 21% of the Company annual turnover.
Coralan, a new treatment for chronic stable angina was registered in November 2006.
In April 2007, Protos, a new treatment for post menopausal osteoporosis was listed on the PBS.
Servier Australia is the local subsidiary of Servier, a leading French research-based pharmaceutical entity, specialising in ethical pharmaceuticals. Employing over 200 people in Australia, its headquarters are in Hawthorn, Melbourne. In 2009 Servier Australia had an annual turnover of $107 million.
Servier Laboratories Limited comprises two principal divisions:
Clinical Research
The management of phase l, ll, lll and lV clinical trials in collaboration with research-based hospitals and general practices throughout Australia.
Sales and Marketing
Sales and Marketing deliver Servier’s portfolio of ethical pharmaceutical products to primary and secondary healthcare professionals
In addition to a team of representatives throughout Australia, to support the operational activities of the above divisions, there is naturally a complete range of professional support functions that include the following: Training, Medical Information (Marketing), Regulatory Affairs, Human Resources, Finance, Information Services, Strategic Coordination, External and Government Relations and Medical Affairs.
Servier Australia offers a range of products in a number of medical areas: cardiovascular disease, especially hypertension and cardiac disease, diabetes and more recently osteoporosis
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is going through globally: the country deals with patent cliffs, companies are…
Can you outline the significance of the current PBS to the industry and in particular the impact it has on service providers to the industry such as Hahn? As service…
Speaking to the Australian environment, how would you rate the market in terms of companies like Swisse? After traveling the world, the Australian market has shown to be one of…
In our interviews we have been hearing two opinions on the success of PBS reforms: that it works as it should in providing space for innovative medicine listings, and that…
Dr Bernadette Morris-Smith has also participated in this interview TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would you begin…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
“Australia is not just a postbox for selling drugs; Celgene is committed to establishing a major presence in the region,” you said when Focus Reports met you first in 2008.…
Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then…
Senior Partner Dr Sree Haran has also participated in this interview. TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would…
The company underwent some landmark changes under your leadership, changing the balance between different pillars of the business – retail, wholesale product delivery, marketing programs. Would you begin by outlining…
After just six months in the country, Novartis Australia’s new Managing Director offers his perspectives on the Australian pharmaceutical market and healthcare system, his company’s commitment to R&D, and…
Can you start by commenting on the state of diabetes in Australia at present? According to 2011 statistics nearly one million Australians have diabetes and about half of those are…
See our Cookie Privacy Policy Here